Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.60 |
| ▸ | AGXT | P21549 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29467207 | 0.87 | IDO1 (0.69) | IDO1AGXTMAOBKDM4ESMN1; SMN2 | |
| SCHEMBL3162264 | 0.84 | IDO1 (0.41) | IDO1AGXTMAOBALKBH1 | |
| SCHEMBL12874169 | 0.80 | IDO1 (0.60) | IDO1AGXTMAOBKDM4ESMN1; SMN2 | |
| SCHEMBL706472 | 0.79 | IDO1 (0.64) | IDO1AGXTMAOBKDM4ESMN1; SMN2 | |
| SCHEMBL3156002 | 0.78 | IDO1 (0.63) | IDO1AGXTDAO | |
| SCHEMBL3160284 | 0.77 | SLC6A4 (0.38) | IDO1AGXTMAOB | |
| SCHEMBL129245 | 0.76 | IDO1 (0.54) | IDO1AGXTMAOBKDM4ESMN1; SMN2 | |
| SCHEMBL22519888 | 0.76 | IDO1 (0.55) | IDO1AGXTMAOBKDM4ESMN1; SMN2 | |
| SCHEMBL10202639 | 0.76 | IDO1 (0.55) | IDO1AGXTMAOBKDM4ESMN1; SMN2 | |
| SCHEMBL29306389 | 0.76 | IDO1 (0.55) | IDO1AGXTMAOBKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| EP-2061789-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008032858-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | IDO1 1716/4885AGXT 3155/4885MAOB 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.